Brains, Bones, and Aging: Psychotropic Medications and Bone Health Among Older Adults
Brains, Bones, and Aging: Psychotropic Medications and Bone Health Among Older Adults
复制标题
DOI：
10.1007/s11914-012-0121-4
复制
发表时间：
2012-12-01
影响因子：
4.3
通讯作者：
Mezuk, Briana
中科院分区：
文献类型：
--
作者：
Brown, Monique J.;Mezuk, Briana
精神药物是治疗精神疾病的关键因素;然而，许多类别的精神药物与老年人骨折风险之间存在既定关联，越来越多的证据表明某些类别的药物也可能影响骨密度（BMD）。在本文中，我们回顾了最近的流行病学研究精神药物和骨质疏松症之间的关联，并讨论了目前的争议和未解决的问题，围绕这种关系。需要重点调查的关键领域包括解决精神药物和BMD之间的明显关联是否是由于适应症的混淆，这种关系是否对男性和女性有所不同，以及这些药物对骨骼健康的影响是否在生命过程中有所不同。还需要进行临床研究，以描述老年人，特别是骨折高危人群使用精神药物的风险/获益比，以促进患者和医生之间的处方决策。
Psychotropic drugs are a crucial element of treatment for psychiatric disorders; however there is an established association between many classes of psychotropic medications and fracture risk among older adults, and growing evidence that some classes of medications may also impact bone mineral density (BMD). In this paper we review recent epidemiologic research on the association between psychotropic medications and osteoporosis, and discuss current controversies and unresolved issues surrounding this relationship. Key areas in need of focused inquiry include resolving whether the apparent association between psychotropic medications and BMD is due to confounding by indication, whether this relationship differs for men and women, and whether the implications of these medications for bone health vary over the life course. Clinical research to delineate the risk/benefit ratio of psychotropic medications for older adults, particularly those who are at high risk for fracture, is also needed to facilitate prescribing decisions between patients and physicians.